TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22446569

Group type: EXPERIMENTAL
Intervention: Mobile phone based monitoring (twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Mobile phone based monitoring
Number of subjects: 288

Group type: COMPARATOR
Intervention: Paper based monitoring
Number of subjects: 288
Study: 20589762

Group type: EXPERIMENTAL
Intervention: health literacy (informational) intervention
Number of subjects: 87
Study: 18931230

Group type: EXPERIMENTAL
Intervention: High fidelity group (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low fidelity group (n = 11)
Number of subjects: 22
Study: 15910636

Group type: EXPERIMENTAL
Intervention: Non-milk drinkers
Number of subjects: 4024

Group type: COMPARATOR
Intervention: Milk drinkers
Number of subjects: 4024
Study: 15226691

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis (one tablet per day)
Number of subjects: 530
Study: 11176321

Group type: EXPERIMENTAL
Intervention: β‐glucan‐enriched bedtime snack
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional snack
Number of subjects: 38
Study: 9431728

Group type: EXPERIMENTAL
Intervention: 1-session exposure and cognitive restructuring (3 hr session)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 5-sessions exposure and cognitive restructuring (6 hr gradual treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1-session exposure and cognitive restructuring
Number of subjects: 28

Group type: COMPARATOR
Intervention: 5-sessions exposure and cognitive restructuring
Number of subjects: 28
Study: 7683222

Group type: EXPERIMENTAL
Intervention: Biofragmentable Anastomosis Ring (BAR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hand-suture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 150
Study: 3306379

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine administered at 3, 4, 6, and 14 months.
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Control group (children born on even-numbered days).
Number of subjects: 60000
Study: 28299947

Group type: EXPERIMENTAL
Intervention: Intervention: 'Start. Transform. Achieve. Results.'
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control
Number of subjects: 693
Study: 28463161

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE self-reporting during treatment
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE self-reporting after treatment
Number of subjects: 152
Study: 25993047

Group type: EXPERIMENTAL
Intervention: Prophylactic extended-field carbon-ion radiotherapy (C-ion RT)
Number of subjects: 26
Study: 24035250

Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab (2×10 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21118028

Group type: EXPERIMENTAL
Intervention: Intensive school-based nutrition education and lifestyle interventions
Number of subjects: 106
Study: 18492520

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (1 x 10(8) colony forming units a day) for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16565959

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg dose of alcohol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14571231

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.20 to 0.33 mg/kg body weight per week for 4 years)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 38
Study: 10910439

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Essential hypertension (no treatment)
Number of subjects: 31
Study: 9010707

Group type: EXPERIMENTAL
Intervention: Matrix-type transdermal therapeutic system (MTTS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Reservoir-type transdermal therapeutic system (RTTS)
Number of subjects: 34
Study: 1558156

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg/100 ml in 5 min)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms/100 ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Captopril and Clonidine
Number of subjects: 42
Study: 4093327

Group type: EXPERIMENTAL
Intervention: Sweet sip feeds (chocolate, strawberry, banana)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Savoury sip feeds
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sweet sip feeds
Number of subjects: 36
Study: 30639153

Group type: EXPERIMENTAL
Intervention: Standard speech pathology intervention (SPI) combined with supplemental pre‐recorded videos for home practice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard speech pathology intervention (SPI) alone
Number of subjects: 18
Study: 31304554

Group type: EXPERIMENTAL
Intervention: Complete excision of the SCJ via endoscopic mucosal resection (EMR) in addition to radiofrequency ablation (RFA) ± EMR of BD/intramucosal EAC (experimental arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard of care (RFA ± EMR) of said lesions (control arm)
Number of subjects: 0
Study: 28414983

Group type: EXPERIMENTAL
Intervention: Hands-and-knees position
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 1400
Study: 25569354

Group type: EXPERIMENTAL
Intervention: Active recovery protocol (2 min standing/walking, 16 min jogging at 58%±5% of VO2peak, 3 min standing/walking)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive recovery protocol (15 min sitting, 3 min walk/jog at 30% of VO2peak, 3 min standing/walking)
Number of subjects: 10
Study: 23864249

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg over a 30 min infusion) every 1 month
Number of subjects: 137

Group type: COMPARATOR
Intervention: Clodronate (4 tablets per day of 1,600 mg)
Number of subjects: 137
Study: 21081641

Group type: EXPERIMENTAL
Intervention: Enhanced Green Prescription intervention (written exercise prescription, brief advice from a primary care nurse, face-to-face follow-up at 6 months, and 9 months of telephone support)
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Enhanced Green Prescription intervention
Number of subjects: 1089
Study: 19293567

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Assessment Scale ‐ Cognitive
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Mini‐Mental State Examination
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Greater-than-average cognitive impairment
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Less-than-average cognitive impairment
Number of subjects: 489
Study: 16729276

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 15503310

Group type: EXPERIMENTAL
Intervention: Irinotecan once every 3 weeks
Number of subjects: 291

Group type: COMPARATOR
Intervention: Weekly irinotecan treatment
Number of subjects: 291
Study: 11317685

Group type: EXPERIMENTAL
Intervention: Titanium implants
Number of subjects: 31

Group type: COMPARATOR
Intervention: Stainless steel implants
Number of subjects: 31
Study: 9446435

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg on the day of operation and 3 x 25 mg orally from postoperative day 1 to 10)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single dose of 6 Gy radiation (administered within postoperative days 1 to 4)
Number of subjects: 50
Study: 7957539

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (1 mg i.v.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Captopril (75 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (matched to captopril, orally)
Number of subjects: 12
Study: 3311818

Group type: EXPERIMENTAL
Intervention: QU.A.RT. group (irradiated on the operated breast with a total dose of 50 Gy plus a limited boost of 10 Gy)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Halsted group (not irradiated)
Number of subjects: 701
Study: 30703663

Group type: EXPERIMENTAL
Intervention: Self-initiated gradual reduction (at least 25% reduction in cigarettes per day)
Number of subjects: 482

Group type: COMPARATOR
Intervention: No reduction or increase in smoking
Number of subjects: 482
Study: 28069156

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) and Guided Imagery (GI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 25791747

Group type: EXPERIMENTAL
Intervention: Healthy school meal programme
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control (usual packed lunch from home)
Number of subjects: 693
Study: 23364497

Group type: EXPERIMENTAL
Intervention: Probiotics-containing biscuit
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21522034

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 181

Group type: COMPARATOR
Intervention: Group educational intervention
Number of subjects: 181
Study: 19207131

Group type: EXPERIMENTAL
Intervention: blue-appearing light (goLITE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: blue-enriched white-appearing light
Number of subjects: 18
Study: 16418883

Group type: EXPERIMENTAL
Intervention: [11C]metahydroxyephedrine (mHED) PET
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: [18F]fluorodeoxyglucose (FDG) PET
Number of subjects: 14

Group type: COMPARATOR
Intervention: MIBG
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PET scanning (mHED and FDG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PET functional imaging
Number of subjects: 14
Study: 15589635

Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization (PTCA, n=109)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Medical therapy (n=103)
Number of subjects: 212
Study: 12623472

Group type: EXPERIMENTAL
Intervention: Two-layered repair
Number of subjects: 823

Group type: COMPARATOR
Intervention: Three-layered repair
Number of subjects: 823
Study: 9707354

Group type: EXPERIMENTAL
Intervention: 20 mg manidipine dihydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients with grade B hepatic impairment
Number of subjects: 20
Study: 7880702

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.25 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.5 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: No suxamethonium (Control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol and alfentanil alone (Control)
Number of subjects: 60
Study: 2099158

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (2 gm) and sulbactam (1 gm)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ampicillin (2 gm) and sulbactam (1 gm)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ampicillin/sulbactam (2 gm/1 gm)
Number of subjects: 6
Study: 33875

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (2 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: High dose sodium cromoglycate (2 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low dose sodium cromoglycate (160 mg/day)
Number of subjects: 70
Study: 30248269

Group type: EXPERIMENTAL
Intervention: MJ-SJ (multi-joint exercises followed by single-joint exercises)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SJ-MJ (single-joint exercises followed by multi-joint exercises)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MJ-SJ
Number of subjects: 36

Group type: COMPARATOR
Intervention: SJ-MJ
Number of subjects: 36
Study: 29039261

Group type: EXPERIMENTAL
Intervention: High-intensity exercise program (9-month, thrice-weekly, 10-minute sessions)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 240
Study: 27343147

Group type: EXPERIMENTAL
Intervention: Home BP telemonitoring alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Home BP telemonitoring plus protocolized pharmacist case management
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Home BP telemonitoring alone and Home BP telemonitoring plus protocolized pharmacist case management
Number of subjects: 300
Study: 24698817

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 40
Study: 22722502

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight management intervention
Number of subjects: 222
Study: 19047322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (after excluding one large trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recent studies (multisite trials)
Number of subjects: 0
Study: 17612822

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day) plus placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day) plus bupropion (50 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15130379

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (n = 178)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Traditional embryo transfer (n = 152)
Number of subjects: 330
Study: 12202072

Group type: EXPERIMENTAL
Intervention: Wheeling Walks campaign promoting 30 min of daily walking through paid media, public relations, and public health activities
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Wheeling Walks campaign promoting 30 min of daily walking
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Wheeling Walks campaign
Number of subjects: 719
Study: 9819794

Group type: EXPERIMENTAL
Intervention: rhEPO 150 U/kg, subcutaneously, three times a week
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: rhEPO 300 U/kg, subcutaneously, three times a week
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (open control)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: rhEPO (both dosages)
Number of subjects: 122
Study: 8624969

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program (ERP) of moderate intensity, frequency, and duration for 3 months, starting approximately 9 weeks post-operatively.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care without ERP, allowing activity/exercise.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both groups reported comparable exercise levels sufficient for training effects to occur.
Number of subjects: 49
Study: 29036330

Group type: EXPERIMENTAL
Intervention: Experimental treatments in multi-arm trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced and outcome-adaptive randomization methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed designs for adding new arms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-arm studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-arm studies
Number of subjects: 0
Study: 27271195

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study: 24691757

Group type: EXPERIMENTAL
Intervention: 24 h sleep deprivation group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 22639299

Group type: EXPERIMENTAL
Intervention: Concentrated bone marrow with autologous bone and ceramics
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unconcentrated bone marrow with autologous bone and ceramics
Number of subjects: 15
Study: 19997775

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 21
Study: 18361007

Group type: COMPARATOR
Intervention: bupivacaine 0.25% (group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plus ketamine 0.5 mg/kg (group BK)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plus tramadol 1 mg/kg (group BT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plus ketamine or bupivacaine 0.25% plus tramadol
Number of subjects: 75
Study: 16818127

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (8 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12657919

Group type: EXPERIMENTAL
Intervention: Itraconazole with co-trimoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itraconazole without co-trimoxazole
Number of subjects: 0
Study: 10758457

Group type: EXPERIMENTAL
Intervention: Midazolam (20 microg kg‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol (20 microg kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg kg‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 8951191

Group type: EXPERIMENTAL
Intervention: Oral artemether (5 mg kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intramuscular artemether (5 mg kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intrarectal artemether (5 mg kg‐1)
Number of subjects: 8
Study: 1431008

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 2413563

Group type: EXPERIMENTAL
Intervention: Topically applied mucopolysaccharide polysulphate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29926901

Group type: EXPERIMENTAL
Intervention: Temperature intervention of 33°C
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Temperature intervention of 36°C
Number of subjects: 950

Group type: COMPARATOR
Intervention: Temperature intervention of 33°C or 36°C
Number of subjects: 950
Study: 26944706

Group type: EXPERIMENTAL
Intervention: Unexpected perturbation of balance exercises during treadmill walking
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treadmill walking with no perturbations
Number of subjects: 53
Study: 25788509

Group type: EXPERIMENTAL
Intervention: Warfarin treatment in PAC
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: CHADS2 score of 2
Number of subjects: 314

Group type: COMPARATOR
Intervention: RE-LY trial
Number of subjects: 314
Study: 24172117

Group type: EXPERIMENTAL
Intervention: Interactive voice response self-monitoring (IVR SM) system with educational modules for 24 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study: 20060783

Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (25 mg aspirin plus 200 mg dipyridamole) twice daily within 24 hours of stroke or TIA onset.
Number of subjects: 543

Group type: COMPARATOR
Intervention: Aspirin plus extended-release dipyridamole (100 mg aspirin) once daily after 7 days of aspirin monotherapy.
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Composite endpoint (non-fatal stroke, TIA, non-fatal myocardial infarction, major bleeding complications, and mortality).
Number of subjects: 543
Study: 17587504

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg/day) + Bupropion SR (300 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupropion SR (300 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naltrexone + Bupropion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupropion only
Number of subjects: 20
Study: 16150793

Group type: EXPERIMENTAL
Intervention: Caffeine capsules (5 mg kg(‐1))
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-dose adrenaline infusion (HAdr; adrenaline concentration, 1.2 nM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low-dose adrenaline infusion (LAdr; adrenaline concentration, 0.75 nM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38
Study: 14656350

Group type: EXPERIMENTAL
Intervention: Allergen-impermeable bed covers for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo bed covers for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allergen-impermeable bed covers
Number of subjects: 0
Study: 10097224

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8889901

Group type: EXPERIMENTAL
Intervention: Tirilazad (2.5 mg/kg every 3 hours for the first 12 hours, then 2.5 mg/kg every 6 hours for a total of 22 doses over 5 days)
Number of subjects: 20
Study: 2068830

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 6369854

Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Gyne T 200
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: MLcu 250
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Tcu 200
Number of subjects: 203
Study: 30059815

Group type: EXPERIMENTAL
Intervention: Strength-oriented psychoeducational programme
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study: 27609859

Group type: EXPERIMENTAL
Intervention: Allopurinol (up to 600 mg daily)
Number of subjects: 5215

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 5215
Study: 24760951

Group type: EXPERIMENTAL
Intervention: Interactive version of the smoking cessation program
Number of subjects: 23213

Group type: EXPERIMENTAL
Intervention: Completion of 4 modules of the intervention
Number of subjects: 23213

Group type: EXPERIMENTAL
Intervention: Smoking 30 minutes after waking
Number of subjects: 23213

Group type: EXPERIMENTAL
Intervention: Smoking 1 hour after waking
Number of subjects: 23213
Study: 22093067

Group type: EXPERIMENTAL
Intervention: 0.25% hexyl nicotinate (HN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5% benzoic acid (BA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.625% benzoic acid (BA)
Number of subjects: 10